orlistat – kdc

CLINICAL USE

Adjunct in obesity

DOSE IN NORMAL RENAL FUNCTION

120 mg taken immediately before, during or up to 1 hour after each meal; maximum 360 mg daily

PHARMACOKINETICS

Molecular weight :495.7

%Protein binding :>99

%Excreted unchanged in urine : 0–4

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :1–2/unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAcarbose: avoid concomitant administration

Anticoagulants: monitor INR more frequently

Ciclosporin: possibly reduces absorption of ciclosporinVitamins: may reduce the absorption of fat soluble vitamins

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

If the meal doesn’t contain any fat, omit orlistatOrlistat is poorly absorbed; bioavailability of less than 5%.

Tags: post-by-auto-php